Chronic Lymphocytic Leukemia Market Value Chain and Forecast 2016-2026


Presentation Description

Future Market Insights has announced the addition of the “ Chronic Lymphocytic Leukemia Market: Global Industry Analysis and Opportunity Assessment 2016-2026”report to their offering.


Presentation Transcript

slide 1:

Trends in the Chronic Lymphocytic Leukemia Market 2016-2026 March 2017 ©2015 Future Market Insights All Rights Reserved Report Id : REP-GB-2481 Status : Ongoing Category : Healthcare Pharmaceuticals Medical Devices

slide 2:

About Future Market Insights ©2015 Future Market Insights All Rights Reserved Future Market Insights FMI is a premier provider of syndicated research reports custom research reports and consulting services. We deliver a complete packaged solution which combines current market intelligence statistical anecdotes technology inputs valuable growth insights aerial view of the competitive framework and future market trends. We provide research services at a global as well as regional level key regions include GCC ASEAN and BRIC. Our offerings cover a broad spectrum of industries including Chemicals Materials Energy Technology Healthcare and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London U.K. with a state-of-the-art delivery center located in Pune India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Subscription Information  Customized Research  Syndicated Research  Investment Research  Social Media Research Sector Coverage  Automotive and Transportation  Electronics Semiconductor and ICT  Retail and Consumer Products  Industrial Automation and Equipment  Chemicals Materials  Food and Beverages  Services and Utilities  Energy Mining Oil and Gas For detailed subscription information please contact Hari. T Sr. Manager - Global Business Development T: +44 0 20 7692 8790 | D: +44 20 3287 4268 Email: Customized Research Syndicated Research Investment Research Social Media Research 2

slide 3:

Research Methodology 1/2 Systematic Research Approach In-depth secondary research is used to ascertain overall market size top industry players top products industry associations etc. PMR formulates a detailed discussion guide to conduct expert and industry interviews PMR develops a list of industry players manufacturers distributors retailers and industry experts PMR conducts interviews with industry experts industry players distributors and retailers Data is validated by triangulation method wherein secondary primary and PMR analysis contribute to the final data Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry PMR delivers industry insights and information in the required format PDF Data Collection Data Filter Analysis Research Intelligence Actionable Insights Business Solution A C B Primary Research Company Analysis Desk Research  Identifying key opinion leaders  Questionnaire design  In-depth interviews  Coverage across value chain  Market participants  Key strengths  Product portfolio  Mapping as per value chain  Key focus segments  Key industry experts  Channel study  Developments  Market dynamics  Products  Conclusions SOLUTION Primary Research  Linkedin  Zoominfo  Salesforce  Avention  Factiva  GBI  Genios  Meltwater  Company websites  Company annual reports  White papers  Financial reports ©2015 Future Market Insights All Rights Reserved Secondary Research Paid Publications Insights Market profiling Formulating discussion guide Developing list of respondents Data analysis Data validation Data collection 1 2 3 4 5 6 7 includes sources of databases 3

slide 4:

Trends in the Chronic Lymphocytic Leukemia Market 2016-2026 Chronic lymphocytic leukemia CLL is a blood and bone marrow disease that usually gets adverse slowly. It is one of the most common types of leukemia in adults. Chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes.It may affect red blood cells white blood cells and platelets. Chronic lymphocytic leukemia is the second most common cancer in adult males. About 90 of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age or middle age. It is rarely seen in people under age 40 and is extremely rare in children. In CLL majority of the blood stem cells become abnormal lymphocytes healthy white blood cells. The abnormal lymphocytes may also be called leukemia cells. These abnormal lymphocytes are not able to fight infection very well. Also as the number of lymphocytes increases in the blood and bone marrow there is less room for healthy white blood cells red blood cells and platelets. This may cause infection anemia and easy bleeding which may result in death. In 2016 American Cancer Society has estimated that in the United States about18960 new cases of chronic lymphocytic leukemia CLLand approximately 4660 deaths by CLL are observed up till now. Chronic Lymphocytic Leukemia Market: Drivers and Restraints Increase in aging population is an impetus for the growth of the CLL market. The increasing incidences of cancers in developed and developing countries such as India and Brazil are expected to boost market growth. Moreover exceptional regulatory designations offered to certain drugs. CLL is a disease which affects a minute percentage of the population t ha t ’ s why they are treated by a few marketed drugs Chronic Lymphocytic Leukemia Market ©2015 Future Market Insights All Rights Reserved 4

slide 5:

only. A small or medium number of patients creates a very small market for these drugs. So it may or may not be profitable for companies to develop these drugs as recovering the research and developments of the drug expenses would be difficult. Th a t ’ s why collaboration agreements and co- development are some of the key strategies adopted by top market players. For example recently GlaxoSmithKline plc and Genmab A/S have entered into co-development and collaboration agreement for drug Arzerra ofatumumab used in the treatment of relapsed CLL. Other two important drivers for CLL treatment market are family history of blood disorders and excessive exposure to harmful chemicals. Another trend that is expected to inspire market growth is a rise in the development of combination of drug therapies. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. Previously approved combinations were only few.However stringent regulatory guidelines are expected to hamper market growth. Moreover the high overall treatment cost for the therapy is another factor inhibiting the market growth. For example GA101/RG7159 was launched in the market in 2014 by Genentech Inc U.S.. The drug costs approximately at 409580 for patients who take them annually. Request Report Sample Chronic Lymphocytic Leukemia Market: Segmentation The global chronic lymphocytic leukemiamarket is classified on the basis of type route of administration type of drug end user. Chronic Lymphocytic Leukemia Market ©2015 Future Market Insights All Rights Reserved 5

slide 6:

Based on type the global chronic lymphocytic leukemiamarket is segmented into the following: Acute myeloid or myelogenous leukemia AML Chronic myeloid or myelogenous leukemia CML Acute lymphocytic or lymphoblastic leukemia ALL Chronic lymphocytic leukemia CLL Based on Drug Route Administration ROA the global chronic Lymphocytic Leukemiamarket is segmented into the following: Oral Parenteral Based on types of chemo drugs used the global chronic lymphocytic leukemiamarket is segmented into the following: Purine analogs. Chronic Lymphocytic Leukemia Market ©2015 Future Market Insights All Rights Reserved 6

slide 7:

Alkylating agents Corticosteroids Other drugs Based on end user global chronic lymphocytic leukemiamarket is segmented into the following: Hospitals Private Clinics Diagnostic Laboratories Research Laboratories Research Institutes Drug Store Request For TOC Chronic Lymphocytic Leukemia Market ©2015 Future Market Insights All Rights Reserved 7

slide 8:

Chronic Lymphocytic Leukemia Market overview: Conventionally the CLL therapeutics market is dominated by the parenteral segment. In the parenteral ROA the drug is administered by the intravenous subcutaneous intrathecal or intramuscular routes. But slowly oral drugs are expected to capture vast market share. Drugs delivered by oral route are absorbed rapidly and the onset of action is fast. Moreover oral ROA is essential during emergencies when there is a need for greater patient compliance. For example: - Imbruvica rituximab idelalisib are oral tablets given to CLL patients alone or in combination. The efficacy of ibrutinib Imbruvica and idelalisib Zydelig in chronic lymphocytic leukemia CLL suggests the drugs could potentially replace chemoimmunotherapy completely for some patients. Chronic Lymphocytic Leukemia Market: Regional Overview Region wise the global chronic lymphocytic leukemiamarket is classified into regions namely North America Latin America Western Europe Eastern Europe Asia-Pacific Japan Middle East and Africa. North America dominated the global market for chronic lymphocytic leukemiadue to good reimbursement policies for diagnostic therapeutic procedures and number of government organizations investigating the efficiency. After North America this market is followed by Europe due to increase in the number of patients suffering from CLL. Asia Pacific region is expected to perceive a significantly faster growth over the forecast period due to a number of branded drugs will become available over the next four years with the expanding patient pool receiving greater access to such new treatments. Chronic Lymphocytic Leukemia Market ©2015 Future Market Insights All Rights Reserved 8

slide 9:

Browse Full Report market Chronic Lymphocytic Leukemia Market: Key Players Some of the key players in the market of near patient molecular solution are F. Hoffman-La Roche AbbVie Teva Pharmaceuticals Gilead Sciences Novartis and Johnson Johnson. Chronic Lymphocytic Leukemia Market ©2015 Future Market Insights All Rights Reserved 9

slide 10:

©2015 Future Market Insights All Rights Reserved Future Market Insights Global Consulting Private Limited FMI Thank You To know more about us please visit our website: For sales queries or new topics email us on: For media queries contact the press office at For other queries contact: Harish Tiwari General Manager Global Head Business Development Future Market Insights: 3rd Floor 207 Regent Street London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: 10